Maraviroc (Maraviroc) Patent Expiration, LOE Window & CMS Spending

Maraviroc (Maraviroc) by Camber Pharmace: Multi-Source Generic Molecule, 4 AB generics, $20.4M 2024 CMS Part D & Medicaid spend, and $1,411 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCamber Pharmace
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$20.4M
2024 Medicare Part D Spend$18.7M
2024 Medicaid Spend$1.7M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,411 intro WAC)